Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist

Beau Norgeot; Giorgio Quer; Brett K. Beaulieu-Jones; Ali Torkamani; Raquel Dias; Milena Gianfrancesco; Rima Arnaout; Isaac S. Kohane; Suchi Saria; Eric Topol; Ziad Obermeyer; Bin Yu; Atul J. Butte

doi:10.1038/s41591-020-1041-y

Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist

Beau Norgeot, Giorgio Quer, Brett K. Beaulieu-Jones, Ali Torkamani, Raquel Dias, Milena Gianfrancesco, Rima Arnaout, Isaac S. Kohane, Suchi Saria, Eric Topol, Ziad Obermeyer, Bin Yu, Atul J. Butte

Research output: Contribution to journal › Comment/debate › peer-review

18 Scopus citations

Original language	English (US)
Pages (from-to)	1320-1324
Number of pages	5
Journal	Nature medicine
Volume	26
Issue number	9
DOIs	https://doi.org/10.1038/s41591-020-1041-y
State	Published - Sep 1 2020
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-020-1041-y

Cite this

@article{514a27e3378445ac8550fd29d96a2a08,

title = "Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist",

author = "Beau Norgeot and Giorgio Quer and Beaulieu-Jones, {Brett K.} and Ali Torkamani and Raquel Dias and Milena Gianfrancesco and Rima Arnaout and Kohane, {Isaac S.} and Suchi Saria and Eric Topol and Ziad Obermeyer and Bin Yu and Butte, {Atul J.}",

note = "Funding Information: I.S.K. is on the scientific advisory boards of Pulse Data and Medaware, both companies involved in predictive analytics. S.S. is a founder of, and holds equity in, Bayesian Health. The results of the study discussed in this publication could affect the value of Bayesian Health. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. S.S. is a member of the scientific advisory board for PatientPing. B.K.B.-J. is a cofounder of Salutary, Inc. B.N. is employed by Anthem. A.J.B. is a cofounder of and consultant to Personalis and NuMedii; consultant to Samsung, Mango Tree Corporation and, in the recent past, 10x Genomics, Helix, Pathway Genomics and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, Merck and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Facebook, Google, Microsoft, 10x Genomics, Amazon, Biogen, Illumina, Snap, Nuna Health, Royalty Pharma, Sanofi, AstraZeneca, Assay Depot, Vet24seven, Regeneron, Moderna and Sutro, many of which use AI and predictive modeling, and several other non-health-related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Genentech, Takeda, Varian, Roche, Pfizer, Merck, Lilly, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Johnson & Johnson, Westat and many academic institutions, state or national agencies, medical or disease specific foundations and associations, and health systems. A.J.B. receives royalty payments through Stanford University for several patents and other disclosures licensed to NuMedii and Personalis. A.J.B. has research funded by the NIH, Northrup Grumman (as the prime on an NIH contract), Genentech, Johnson & Johnson, FDA, US Department of Defense, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, Barbara and Gerson Bakar Foundation and, in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor{\textquoteright}s Office of Planning and Research, California Institute for Regenerative Medicine, L{\textquoteright}Oreal and Progenity.",

year = "2020",

month = sep,

day = "1",

doi = "10.1038/s41591-020-1041-y",

language = "English (US)",

volume = "26",

pages = "1320--1324",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Minimum information about clinical artificial intelligence modeling

T2 - the MI-CLAIM checklist

AU - Norgeot, Beau

AU - Quer, Giorgio

AU - Beaulieu-Jones, Brett K.

AU - Torkamani, Ali

AU - Dias, Raquel

AU - Gianfrancesco, Milena

AU - Arnaout, Rima

AU - Kohane, Isaac S.

AU - Saria, Suchi

AU - Topol, Eric

AU - Obermeyer, Ziad

AU - Yu, Bin

AU - Butte, Atul J.

N1 - Funding Information: I.S.K. is on the scientific advisory boards of Pulse Data and Medaware, both companies involved in predictive analytics. S.S. is a founder of, and holds equity in, Bayesian Health. The results of the study discussed in this publication could affect the value of Bayesian Health. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. S.S. is a member of the scientific advisory board for PatientPing. B.K.B.-J. is a cofounder of Salutary, Inc. B.N. is employed by Anthem. A.J.B. is a cofounder of and consultant to Personalis and NuMedii; consultant to Samsung, Mango Tree Corporation and, in the recent past, 10x Genomics, Helix, Pathway Genomics and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, Merck and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Facebook, Google, Microsoft, 10x Genomics, Amazon, Biogen, Illumina, Snap, Nuna Health, Royalty Pharma, Sanofi, AstraZeneca, Assay Depot, Vet24seven, Regeneron, Moderna and Sutro, many of which use AI and predictive modeling, and several other non-health-related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Genentech, Takeda, Varian, Roche, Pfizer, Merck, Lilly, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Johnson & Johnson, Westat and many academic institutions, state or national agencies, medical or disease specific foundations and associations, and health systems. A.J.B. receives royalty payments through Stanford University for several patents and other disclosures licensed to NuMedii and Personalis. A.J.B. has research funded by the NIH, Northrup Grumman (as the prime on an NIH contract), Genentech, Johnson & Johnson, FDA, US Department of Defense, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, Barbara and Gerson Bakar Foundation and, in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor’s Office of Planning and Research, California Institute for Regenerative Medicine, L’Oreal and Progenity.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85090819900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090819900&partnerID=8YFLogxK

U2 - 10.1038/s41591-020-1041-y

DO - 10.1038/s41591-020-1041-y

M3 - Comment/debate

C2 - 32908275

AN - SCOPUS:85090819900

SN - 1078-8956

VL - 26

SP - 1320

EP - 1324

JO - Nature medicine

JF - Nature medicine

IS - 9

ER -

Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this